WWA
RPRX icon

Wealth Watch Advisors’s Royalty Pharma RPRX Stock Holding History

Wealth Watch Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$39 – 715
2025
Q4 		$39 Hold
1
– – ﹤0.01% 949
2025
Q3 		$35 Buy
+1
New +$36 ﹤0.01% 914

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wealth Watch Advisors's RPRX Position: Q1 2026 in Review

Wealth Watch Advisors sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 1 share — an estimated $39 sold.

Wealth Watch Advisors first reported a position in RPRX in Q3 2025 and held it in 2 quarters. The position peaked at $39 in Q4 2025. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Wealth Watch Advisors reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
  • Wealth Watch Advisors sold 1 Royalty Pharma share in Q1 2026, an estimated $39.
  • Wealth Watch Advisors first reported a position in Royalty Pharma in Q3 2025 and held it in 2 quarters.
  • Wealth Watch Advisors's Royalty Pharma position peaked at $39 in Q4 2025.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Wealth Watch Advisors's 13F filing for Q1 2026, filed 15 May 2026.